{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:11:11Z","timestamp":1792429871667,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Aims\/hypothesis<\/jats:title>\n<jats:p>The risk of complications and medical consequences of type 2 diabetes are well known. Hospital costs have been identified as a key driver of total costs in studies of the economic burden of type 2 diabetes. Less evidence has been generated on the impact of individual diabetic complications on the overall societal burden. The objective of this study was to analyse costs of hospital-based healthcare (inpatient and outpatient care) and work absence related to individual macrovascular and microvascular complications of type 2 diabetes in Sweden in 2016.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Data for 2016 were retrieved from a Swedish national retrospective observational database cross-linking individual-level data for 1997\u20132016. The database contained information from population-based health, social insurance and socioeconomic registers for 392,200 people with type 2 diabetes and matched control participants (5:1). Presence of type 2 diabetes and of diabetes complications were derived using all years, 1997\u20132016. Costs of hospital-based care and of absence from work due to diabetes complications were estimated for the year 2016. Regression analysis was used for comparison with control participants to attribute absence from work to individual complications, and to account for joint presence of complications.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Use of hospital care for complications was higher in type 2 diabetes compared with control participants in 2016: 26% vs 12% had \u22651 hospital contact; there were 86,104 vs 24,608 outpatient visits per 100,000 people; and there were 9894 vs 2546 inpatient admissions per 100,000 people (all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The corresponding total costs of hospital-based care for complications were \u20ac919 vs \u20ac232 per person (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and 74.7% of costs were then directly attributed to diabetes (\u20ac687 per person). Regression analyses distributed the costs of days absent from work across diabetes complications per se, basic type 2 diabetes effect and unattributed causes. Diabetes complications amounted to \u20ac1317 per person in 2016, accounting for possible complex interactions (25% of total costs of days absent). Key drivers of costs were the macrovascular complications angina pectoris, heart failure and stroke; and the microvascular complications eye diseases, including retinopathy, kidney disease and neuropathy. Early mortality in working ages cost an additional \u20ac579 per person and medications used in risk-factor treatment amounted to \u20ac418 per person.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions\/interpretation<\/jats:title>\n<jats:p>The economic burden of complications in type 2 diabetes is substantial. Costs of absence from work in this study were found to be greater than of hospital-based care, highlighting the need for considering treatment consequences in a societal perspective in research and policy.<\/jats:p>\n<jats:p>Graphical abstract<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00125-020-05277-3","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T01:33:22Z","timestamp":1600911202000},"page":"2582-2594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden"],"prefix":"10.1007","volume":"63","author":[{"given":"Emelie","family":"Andersson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-0908","authenticated-orcid":false,"given":"Sofie","family":"Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino","family":"Hall\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5sa","family":"Ericsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desir\u00e9e","family":"Thielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8238-8189","authenticated-orcid":false,"given":"Peter","family":"Lindgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2325-5634","authenticated-orcid":false,"given":"Katarina","family":"Steen Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1025-1682","authenticated-orcid":false,"given":"Johan","family":"Jendle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"issue":"10027","key":"5277_CR1","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(16)00618-8","volume":"387","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2016","unstructured":"NCD Risk Factor Collaboration (NCD-RisC) (2016) Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 387(10027):1513\u20131530. https:\/\/doi.org\/10.1016\/S0140-6736(16)00618-8","journal-title":"Lancet"},{"key":"5277_CR2","unstructured":"International Diabetes Federation (IDF) (2019) IDF Diabetes Atlas 9th edition. Available from http:\/\/www.diabetesatlas.org\/en\/. Accessed 19 Nov 2019"},{"key":"5277_CR3","unstructured":"Organisation for Economic Co-operation and Development (OECD) (2019) OECD Health Statistics 2019. Available from http:\/\/www.oecd.org\/els\/health-systems\/health-data.htm. Accessed 4 Dec 2019"},{"issue":"5","key":"5277_CR4","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2337\/dci18-0007","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association (2018) Economic costs of diabetes in the U.S. in 2017. Diabetes Care 41(5):917\u2013928. https:\/\/doi.org\/10.2337\/dci18-0007","journal-title":"Diabetes Care"},{"issue":"7","key":"5277_CR5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/j.1464-5491.2012.03698.x","volume":"29","author":"N Hex","year":"2012","unstructured":"Hex N, Bartlett C, Wright D, Taylor M, Varley D (2012) Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med 29(7):855\u2013862. https:\/\/doi.org\/10.1111\/j.1464-5491.2012.03698.x","journal-title":"Diabet Med"},{"key":"5277_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/618039","volume":"2013","author":"J S\u00f8rensen","year":"2013","unstructured":"S\u00f8rensen J, Ploug UJ (2013) The cost of diabetes-related complications: registry-based analysis of days absent from work. Econ Res Int 2013:1\u20138. https:\/\/doi.org\/10.1155\/2013\/618039","journal-title":"Econ Res Int"},{"issue":"1","key":"5277_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40273-018-0699-1","volume":"37","author":"K K\u00e4hm","year":"2019","unstructured":"K\u00e4hm K, Laxy M, Schneider U, Holle R (2019) Exploring different strategies of assessing the economic impact of multiple diabetes-associated complications and their interactions: a large claims-based study in Germany. Pharmacoeconomics 37(1):63\u201374. https:\/\/doi.org\/10.1007\/s40273-018-0699-1","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"5277_CR8","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2337\/dc17-1763","volume":"41","author":"K K\u00e4hm","year":"2018","unstructured":"K\u00e4hm K, Laxy M, Schneider U, Rogowski WH, Lhachimi SK, Holle R (2018) Health care costs associated with incident complications in patients with type 2 diabetes in Germany. Diabetes Care 41(5):971\u2013978. https:\/\/doi.org\/10.2337\/dc17-1763","journal-title":"Diabetes Care"},{"issue":"4","key":"5277_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s41669-017-0063-y","volume":"2","author":"D Nathanson","year":"2018","unstructured":"Nathanson D, Sabale U, Eriksson JW et al (2018) Healthcare cost development in a type 2 diabetes patient population on glucose-lowering drug treatment: a nationwide observational study 2006\u20132014. PharmacoEcon - Open 2(4):393\u2013402. https:\/\/doi.org\/10.1007\/s41669-017-0063-y","journal-title":"PharmacoEcon - Open"},{"issue":"5","key":"5277_CR10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.pcd.2015.01.001","volume":"9","author":"U Sabale","year":"2015","unstructured":"Sabale U, Bodegard J, Sundstrom J et al (2015) Healthcare utilization and costs following newly diagnosed type-2 diabetes in Sweden: a follow-up of 38,956 patients in a clinical practice setting. Prim Care Diabetes 9(5):330\u2013337. https:\/\/doi.org\/10.1016\/j.pcd.2015.01.001","journal-title":"Prim Care Diabetes"},{"issue":"10","key":"5277_CR11","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/dme.12716","volume":"32","author":"S Jansson","year":"2015","unstructured":"Jansson S, Fall K, Brus O et al (2015) Prevalence and incidence of diabetes mellitus: a nationwide population-based pharmaco-epidemiological study in Sweden. Diabet Med 32(10):1319\u20131328. https:\/\/doi.org\/10.1111\/dme.12716","journal-title":"Diabet Med"},{"issue":"11","key":"5277_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3238\/arztebl.2016.0177","volume":"113","author":"T Tamayo","year":"2016","unstructured":"Tamayo T, Brinks R, Hoyer A, Ku\u00df OS, Rathmann W (2016) The prevalence and incidence of diabetes in Germany. Dtsch Arztebl Int 113(11):177\u2013182. https:\/\/doi.org\/10.3238\/arztebl.2016.0177","journal-title":"Dtsch Arztebl Int"},{"issue":"6","key":"5277_CR13","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/dom.12889","volume":"19","author":"T Nystr\u00f6m","year":"2017","unstructured":"Nystr\u00f6m T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW (2017) Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes Obes Metab 19(6):831\u2013841. https:\/\/doi.org\/10.1111\/dom.12889","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"5277_CR14","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/dme.13266","volume":"34","author":"S Adamsson Eryd","year":"2017","unstructured":"Adamsson Eryd S, Svensson AM, Franz\u00e9n S, Eliasson B, Nilsson PM, Gudbj\u00f6rnsdottir S (2017) Risk of future microvascular and macrovascular disease in people with type 1 diabetes of very long duration: a national study with 10-year follow-up. Diabet Med 34(3):411\u2013418. https:\/\/doi.org\/10.1111\/dme.13266","journal-title":"Diabet Med"},{"issue":"5","key":"5277_CR15","doi-asserted-by":"publisher","first-page":"e62650","DOI":"10.1371\/journal.pone.0062650","volume":"8","author":"AA Kiadaliri","year":"2013","unstructured":"Kiadaliri AA, Gerdtham U-G, Nilsson P, Eliasson B, Gudbj\u00f6rnsdottir S, Steen Carlsson K (2013) Towards renewed health economic simulation of type 2 diabetes: risk equations for first and second cardiovascular events from Swedish register data. PLoS One 8(5):e62650. https:\/\/doi.org\/10.1371\/journal.pone.0062650","journal-title":"PLoS One"},{"key":"5277_CR16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ehb.2016.09.003","volume":"23","author":"S Persson","year":"2016","unstructured":"Persson S, Gerdtham UG, Steen Carlsson K, Swedish Childhood Diabetes Study Group (2016) Labor market consequences of childhood onset type 1 diabetes. Econ Hum Biol 23:180\u2013192. https:\/\/doi.org\/10.1016\/j.ehb.2016.09.003","journal-title":"Econ Hum Biol"},{"key":"5277_CR17","doi-asserted-by":"publisher","first-page":"h3234","DOI":"10.1136\/bmj.h3234","volume":"350","author":"I Steineck","year":"2015","unstructured":"Steineck I, Cederholm J, Eliasson B et al (2015) Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. BMJ 350:h3234. https:\/\/doi.org\/10.1136\/bmj.h3234","journal-title":"BMJ"},{"issue":"4","key":"5277_CR18","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2337\/dc18-1850","volume":"42","author":"E Toresson Grip","year":"2019","unstructured":"Toresson Grip E, Svensson A-M, Miftaraj M et al (2019) Real-world costs of continuous insulin pump therapy and multiple daily injections for type 1 diabetes: a population-based and propensity-matched cohort from the Swedish National Diabetes Register. Diabetes Care 42(4):545\u2013552. https:\/\/doi.org\/10.2337\/dc18-1850","journal-title":"Diabetes Care"},{"issue":"2","key":"5277_CR19","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00125-017-4472-3","volume":"61","author":"S Persson","year":"2018","unstructured":"Persson S, Dahlquist G, Gerdtham U-G, Steen Carlsson K (2018) Why childhood-onset type 1 diabetes impacts labour market outcomes: a mediation analysis. Diabetologia 61(2):342\u2013353. https:\/\/doi.org\/10.1007\/s00125-017-4472-3","journal-title":"Diabetologia"},{"issue":"6","key":"5277_CR20","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1007\/s00125-013-2870-8","volume":"56","author":"S Persson","year":"2013","unstructured":"Persson S, Dahlquist G, Gerdtham U-G, Steen Carlsson K (2013) Impact of childhood-onset type 1 diabetes on schooling: a population-based register study. Diabetologia 56(6):1254\u20131262. https:\/\/doi.org\/10.1007\/s00125-013-2870-8","journal-title":"Diabetologia"},{"issue":"6","key":"5277_CR21","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1007\/s00125-009-1625-z","volume":"53","author":"K Steen Carlsson","year":"2010","unstructured":"Steen Carlsson K, Landin-Olsson M, Nystrom L et al (2010) Long-term detrimental consequences of the onset of type 1 diabetes on annual earnings\u2014evidence from annual registry data in 1990\u20132005. Diabetologia 53(6):1084\u20131092. https:\/\/doi.org\/10.1007\/s00125-009-1625-z","journal-title":"Diabetologia"},{"issue":"9","key":"5277_CR22","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/dom.14070","volume":"22","author":"S Persson","year":"2020","unstructured":"Persson S, Johansen P, Andersson E et al (2020) Days absent from work as a result of complications associated with type 2 diabetes: evidence from 20 years of linked national registry data in Sweden. Diabetes Obes Metab 22(9):1586\u20131597. https:\/\/doi.org\/10.1111\/dom.14070","journal-title":"Diabetes Obes Metab"},{"key":"5277_CR23","unstructured":"National Board of Health and Welfare (NBHW) (2019) The National Patient Register. Available from http:\/\/www.socialstyrelsen.se\/en\/statistics-and-data\/registers\/register-information\/the-national-patient-register\/. Accessed 4 Nov 2019"},{"key":"5277_CR24","unstructured":"National Board of Health and Welfare (NBHW) (2019) L\u00e4kemedelsregistret [in Swedish; National Prescribed Drugs Register]. Available from http:\/\/www.socialstyrelsen.se\/statistik-och-data\/register\/alla-register\/lakemedelsregistret\/. Accessed 4 Nov 2019"},{"key":"5277_CR25","unstructured":"Statistics Sweden (2019) Longitudinal integrated database for health insurance and labour market studies (LISA). Available from http:\/\/www.scb.se\/en\/services\/guidance-for-researchers-and-universities\/vilka-mikrodata-finns\/longitudinella-register\/longitudinal-integrated-database-for-health-insurance-and-labour-market-studies-lisa\/. Accessed 4 Nov 2019"},{"key":"5277_CR26","unstructured":"F\u00f6rs\u00e4kringskassan (the Swedish Social Insurance Agency) (2019) MicroData for Analysis of Social Insurance (MiDAS) [in Swedish]. Available from http:\/\/www.forsakringskassan.se\/statistik\/kontakta-statistikenheten. Accessed 22 Nov 2019"},{"key":"5277_CR27","unstructured":"National Board of Health and Welfare (NBHW) (2016) V\u00e4gledning till NordDRG\u2014Svensk version 2016 [in Swedish: Instructions for NordDRG\u2014Swedish version 2016]. Available from http:\/\/www.socialstyrelsen.se\/utveckla-verksamhet\/e-halsa\/klassificering-och-koder\/drg\/. Accessed 22 Nov 2019"},{"key":"5277_CR28","unstructured":"National Board of Health and Welfare (NBHW) (2019) Referensvikter f\u00f6r slutenv\u00e5rds-och \u00f6ppenv\u00e5rdsgrupper, NordDRG 2016 [in Swedish; Reference weights for inpatient and outpatient groups, NordDRG 2016]. Available from http:\/\/www.socialstyrelsen.se\/utveckla-verksamhet\/e-halsa\/klassificering-och-koder\/drg\/. Accessed 22 Nov 2019"},{"key":"5277_CR29","unstructured":"F\u00f6rs\u00e4kringskassan (the Swedish Social Insurance Agency) (2020) Sickness compensation. Available from http:\/\/www.forsakringskassan.se\/myndigheter_old\/arbetsformedlingen\/forsakring\/!ut\/p\/z1\/hZBBT8MwDIV_Ta-xV9SRcuskYEVCmrTDSi4oZW4arUmmJFD49xjEBQk6n_zk7z1ZDxR0oLx-s0ZnG7yeWD-p9bMs8XGzWTUo9yixrbf17V1d3ldYwuEbwH-mQVDL_j15zlBL2K66vgC0qwtAWf0AC48-gBpOwn34ozUjZYpCx55yGkJ0dJysN-QFi6RPkYWINOreTpZJlon4kLPn9au0xvdX0oCKNFDkqNfIXY45n9NNgQXO8yxMCGYi8RJcgX9ZxpAydL9JOLvuvbU7d5Cp-QR3noxh\/dz\/d5\/L2dJQSEvUUt3QS80TmxFL1o2XzgyME1CQjFBMDhTMDgwSTlIOUVGOTJHUDU3\/. Accessed 15 June 2020"},{"key":"5277_CR30","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW (2015) Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford"},{"issue":"8","key":"5277_CR31","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/hec.1653","volume":"20","author":"B Mihaylova","year":"2011","unstructured":"Mihaylova B, Briggs A, O'Hagan A, Thompson S (2011) Review of statistical methods for analysing healthcare resources and costs. Health Econ 20(8):897\u2013916. https:\/\/doi.org\/10.1002\/hec.1653","journal-title":"Health Econ"},{"issue":"1","key":"5277_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/00019053-200927010-00008","volume":"27","author":"U-G Gerdtham","year":"2009","unstructured":"Gerdtham U-G, Clarke P, Hayes A, Gudbjornsdottir S (2009) Estimating the cost of diabetes mellitus-related events from inpatient admissions in Sweden using administrative hospitalization data. Pharmacoeconomics 27(1):81\u201390. https:\/\/doi.org\/10.2165\/00019053-200927010-00008","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"5277_CR33","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40273-019-00775-8","volume":"37","author":"H Shao","year":"2019","unstructured":"Shao H, Yang S, Fonseca V, Stoecker C, Shi L (2019) Estimating quality of life decrements due to diabetes complications in the United States: the Health Utility Index (HUI) diabetes complication equation. Pharmacoeconomics 37(7):921\u2013929. https:\/\/doi.org\/10.1007\/s40273-019-00775-8","journal-title":"Pharmacoeconomics"},{"key":"5277_CR34","unstructured":"Swedish National Diabetes Register (NDR) (2017) Nationella Diabetesregistret\u2014\u00c5rsrapport 2016 [in Swedish; Swedish National Diabetes Register\u2014Annual Report 2016 ]. Available from http:\/\/www.ndr.nu\/#\/arsrapport. Accessed 5 Feb 2020"},{"issue":"6","key":"5277_CR35","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/j.1464-5491.2008.02444.x","volume":"25","author":"A-B Wirehn","year":"2008","unstructured":"Wirehn A-B, Andersson A, \u00d6stgren C-J, Carstensen J (2008) Age-specific direct healthcare costs attributable to diabetes in a Swedish population: a register-based analysis. Diabet Med 25(6):732\u2013737. https:\/\/doi.org\/10.1111\/j.1464-5491.2008.02444.x","journal-title":"Diabet Med"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-020-05277-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-020-05277-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-020-05277-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T06:13:16Z","timestamp":1632463996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-020-05277-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5277"],"URL":"https:\/\/doi.org\/10.1007\/s00125-020-05277-3","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,24]]},"assertion":[{"value":"22 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Four authors are employees of the Swedish Institute for Health Economics (EA, SP, PL, KSC), and three authors are employees of Novo Nordisk (NH, \u00c5E, DT). The authors had the final responsibility for submitting the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}}]}}